BioVersys Announces Financial Results and Business Update

BioVersys AG, a clinical stage biopharmaceutical company based in Basel, Switzerland, will publish its half-year 2026 financial results on September 9. The company focuses on creating new antibacterial products targeting severe infections by multi-drug resistant bacteria. These results will be released at 7:00 AM CET and will be followed by a conference call at 2:00 PM CET, where management will discuss financial outcomes, provide a business update, and outline strategic plans.

During the conference, investors, analysts, and media representatives will have the opportunity to ask questions. The company aims to address the demand for new treatments against resistant bacterial infections through its advanced research programs targeting pathogens like Acinetobacter baumannii and tuberculosis.